Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost : a prospective multicenter study
Martínez, Evelyn (Institut Català d'Oncologia)
Garin, Olatz (Institut Hospital del Mar d'Investigacions Mèdiques)
Pardo Cladellas, Yolanda (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Fernández, Pablo (Instituto Oncológico de Guipuzkoa, San Sebastián)
Guix, Benjamin (Fundación IMOR, Institut Mèdic Onco-Radioterapia, Barcelona)
Gutiérrez, Cristina (Institut Català d'Oncologia)
Boladeras, Ana (Institut Català d'Oncologia)
Ferrer i Julià, Ferran (Institut Català d'Oncologia)
Hernández, Tania (Institut Català d'Oncologia)
Ayala, Adriana (Instituto Oncológico de Guipuzkoa, San Sebastián)
Egiguren, Mikel (Instituto Oncológico de Guipuzkoa, San Sebastián)
Fernández, Gema (Hospital Universitario Central de Asturias)
Muñoz, Víctor (Hospital do Meixoeiro, Vigo)
Macías Hernández, Víctor (Hospital Universitari i Politècnic La Fe (València))
Pera, Joan (Institut Català d'Oncologia)
Pont, Àngels (Institut Hospital del Mar d'Investigacions Mèdiques)
Ferrer Forés, Maria Montserrat (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Guedea, Ferran (Institut Català d'Oncologia)

Data:	2021
Resum:	Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa. Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v. 2), EPIC, and FACT-G and FACT-P questionnaires. A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0. 028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups. After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra, i la creació d'obres derivades, sempre que no sigui amb finalitats comercials i que es distribueixin sota la mateixa llicència que regula l'obra original. Cal que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Quality of life ; Prostate cancer ; External beam radiotherapy ; High-dose-rate brachytherapy
Publicat a:	Journal of Contemporary Brachytherapy, Vol. 13 (february 2021) , p. 1-11, ISSN 2081-2841

DOI: 10.5114/jcb.2021.103580
PMID: 34025730

11 p, 299.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats